ArticleProbiotics and antimicrobial proteins2026
Limosilactobacillus reuteri DSM17938 Attenuates Neuroinflammatory Responses After Spinal Cord Injury by Modulating Tryptophan Metabolism.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis of research on spinal cord injury and the gut microbiota.Frontiers in microbiology · 2026Pooled it
- A new paradigm of bidirectional regulation of the gut-spinal cord axis.Neural regeneration research · 2026Article
- Article
- Oral Lysozyme Attenuates Neuroinflammation and Brain Injury After Traumatic Brain Injury Through Gut Microbiota-Dependent Reprogramming of Tryptophan Metabolism.CNS neuroscience & therapeutics · 2026Article
- Buyang Huanwu Decoction promotes neurorepair after spinal cord injury through a Lactobacillus johnsonii-indole-3-lactic acid-AhR-PI3K/Akt axis.Chinese medicine · 2026Article
- Limosilactobacillus reuteri fermentation enhances the anti-type 2 diabetic activity of Gastrodia elata polysaccharides.AMB Express · 2026Article
- Bidirectional communication between spinal cord injury and gut microbiota, from the bench to the bedside.Frontiers in immunology · 2026Review
- Gut-derived signals regulating glial activation and secondary neuroinflammation after spinal cord injury: an evidence mapping and mechanistic framework.Frontiers in cellular neuroscience · 2026Review
- The neuroinflammatory triumvirate: NF-κB, NLRP3, and mTOR in spinal cord injury.Inflammopharmacology · 2025Review
- Gut Microbes and Inflammation: Their Role in Spinal Cord Injury Progression and Secondary Damage.Current microbiology · 2025Review
- Gut-Spinal Cord Axis in Spinal Cord Injury: Bidirectional Inflammatory Mechanisms and Microbiota-Targeted Therapeutic Strategies.Journal of inflammation research · 2025Review
- Exploring gut microbiota and spinal cord injury: pathogenesis, treatment strategies and prospects.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Spinal cord injury (SCI) disrupts gut flora and exacerbates neuroinflammation. Evidence supports the important role of the intestinal microbiota in SCI. This study evaluated the neuroprotective effect of Limosilactobacillus reuteri (L. reuteri) DSM 17938 on SCI and its potential anti-inflammatory mechanism. The intestinal microbiota was disorganised following SCI, with a significant decrease in the abundance of probiotic bacteria such as L. reuteri. L. reuteri DSM17938 treatment improved the spinal cord pathology and enhanced locomotor functional recovery in SCI-model rats. Moreover, it modulated tryptophan metabolism by promoting indole-3-carboxaldehyde production. In addition, L. reuteri DSM17938 inhibits polarization of M1 microglia and reduces the production of IL-6, IL-1 β, and TNF-α in spinal cord injury to alleviate neuroinflammation. It also activates aryl hydrocarbon receptor (AhR) signalling via upregulating AhR and CYP1A1 expression, promoting tight junction protein synthesis. In summary, L. reuteri DSM17938 promotes SCI recovery by modulating tryptophan metabolism to activate AhR signalling and intestinal barrier repair to attenuate spinal cord M1 microglial activation and neuroinflammation, suggesting a strategy for clinical adjuvant SCI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.